DJ-927 is a novel
taxane, which was selected for high solubility, non-neurotoxicity, oral bioavailability, and potent antitumor activity. In this study, we compared the in vitro and in vivo efficacy of
DJ-927 with those of
paclitaxel and
docetaxel.
DJ-927 exhibited stronger cytotoxicity than
paclitaxel and
docetaxel in various tumor cell lines, especially against
P-glycoprotein (P-gp)-expressing cells. The cytotoxicity of
DJ-927, unlike those of other
taxanes, was not affected by the P-gp expression level in
tumor cells, or by the co-presence of a P-gp modulator. When intracellular accumulation of the three compounds was compared, intracellular amounts of
DJ-927 were much higher than those of
paclitaxel or
docetaxel, particularly in P-gp-positive cells. In vivo,
DJ-927 showed potent antitumor effects against two human solid
tumors in male BALB/c-nu/nu mice, and yielded significant
life-prolongation in a murine liver
metastasis model with male C57BL/6 mice, in which neither
paclitaxel nor
docetaxel was effective. The results demonstrate the superior efficacy of orally administered
DJ-927 over intravenously administered
paclitaxel or
docetaxel against P-gp-expressing
tumors, probably due to higher intracellular accumulation. A phase I clinical trials of
DJ-927 is currently ongoing in the US.